Education:
BS 1990 Biology - Saint Joseph's University
MS 1992 Molecular Biology - Rutgers University
PhD 1996 Cell and Developmental Biology - Rutgers University/ The University of Medicine and Dentistry of New Jersey
Postdoctoral Research Fellowship:
1996 - 2000 School of Osteopathic Medicine, Stratford, New Jersey
Started at USC: 2005 Research Topics: Cell Cycle, Growth & Proliferation, Cancer Cell Biology, DNA & RNA, Drug Design, Delivery
Research Description
Regulation and post-translational modification of enzymes involved in thymidylate nucleotide metabolism
Biochemical mechanisms of action of thymidylate synthase inhibitors
Development and validation of molecular targets for cancer chemotherapeutic drug development
Development and validation of prognostic markers in gastrointestinal cancers
10 Selected Publications:
Click here to view all the publications for this faculty
Labonte MJ,Manegold PC,Wilson PM,Fazzone W,Louie SG,Lenz HJ,Ladner RD - The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. - Int J Cancer [2009] Jun 17;(): PubMed
Fazzone W,Wilson PM,Labonte MJ,Lenz HJ,Ladner RD - Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. - Int J Cancer [2009] Feb 27;(): PubMed
Kumar SR,Scehnet JS,Ley EJ,Singh J,Krasnoperov V,Liu R,Manchanda PK,Ladner RD,Hawes D,Weaver FA,Beart RW,Singh G,Nguyen C,Kahn M,Gill PS - Preferential Induction of EphB4 over EphB2 and Its Implication in Colorectal Cancer Progression. - Cancer Res [2009] Apr 14;(): PubMed
Rhodes KE,Zhang W,Yang D,Press OA,Gordon M,Vallböhmer D,Schultheis AM,Lurje G,Ladner RD,Fazzone W,Iqbal S,Lenz HJ - ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. - Drug Metab Lett [2007] Jan;1(1):23-30 PubMed
Wilson PM,Ladner RD,Lenz HJ - Predictive and prognostic markers in colorectal cancer. - Gastrointest Cancer Res [2007] Nov;1(6):237-46 PubMed
Wilson PM,Fazzone W,LaBonte MJ,Lenz HJ,Ladner RD - Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. - Nucleic Acids Res [2009] Jan;37(1):78-95 PubMed
Wilson PM,Fazzone W,LaBonte MJ,Deng J,Neamati N,Ladner RD - Novel opportunities for thymidylate metabolism as a therapeutic target. - Mol Cancer Ther [2008] Sep;7(9):3029-37 PubMed
Wilson PM,Ladner RD,Lenz HJ - Exploring alternative individualized treatment strategies in colorectal cancer. - Clin Colorectal Cancer [2007] Dec;7 Suppl 1():S28-36 PubMed
Koehler SE,Ladner RD - Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. - Mol Pharmacol [2004] Sep;66(3):620-6 PubMed
Mandola MV,Stoehlmacher J,Zhang W,Groshen S,Yu MC,Iqbal S,Lenz HJ,Ladner RD - A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. - Pharmacogenetics [2004] May;14(5):319-27 PubMed
| |
